BTG International Canada Inc., part of the global specialist healthcare company BTG has received approval from Health Canada for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead that can be loaded with doxorubicin or irinotecan for the local treatment of tumours in patients with hepatocellular carcinoma (HCC) and malignant colorectal cancer metastasized to the liver (mCRC).

DC Bead LUMI is a next generation development of DC Bead that enables real-time visible confirmation of bead location during embolization. This innovative new technology has the potential to provide interventional radiologists increased control, enabling real-time adjustments to optimize patient treatment. The lasting radiopacity of DC Bead LUMI also means it will also be visible in follow-up scans, allowing precise evaluation of the completeness of tumour treatment.

Brad Pearson, director, commercial operations at BTG International Canada Inc., commented, “DC Bead LUMI reinforces our leadership in embolization technology and our focus on bringing to market innovative products that better serve specialist physicians and their patients. We are excited by the potential to offer a new standard of care and look forward to providing DC Bead LUMI to Canadian physicians during the second half of 2016.”

BTG anticipates securing regulatory clearances for additional radiopaque bead products in other markets worldwide.